In terms of treatment combinations, tremelimumab (a fully human mAb against CTLA-4), Vigil vaccine for cervical cancer, bevacizumab, and chemotherapy were paired with PD-1/PD-L1 inhibitors throughout these studies (Table 3). This evidence concerns the gene CTLA4 and cervical cancer.